1335247-35-2

Basic information

• Product Name: N,N'-bis[2-(4-bromophenyl)ethyl]pyrido[2,3-d]pyrimidine-2,4-diamine hydrochloride
• Synonyms: N,N'-bis[2-(4-bromophenyl)ethyl]pyrido[2,3-d]pyrimidine-2,4-diamine hydrochloride
• CAS NO: 1335247-35-2
• Molecular Weight: 563.722
• Mol File: 1335247-35-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N,N'-bis[2-(4-bromophenyl)ethyl]pyrido[2,3-d]pyrimidine-2,4-diamine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: N,N'-bis[2-(4-bromophenyl)ethyl]pyrido[2,3-d]pyrimidine-2,4-diamine hydrochloride(1335247-35-2)
• EPA Substance Registry System: N,N'-bis[2-(4-bromophenyl)ethyl]pyrido[2,3-d]pyrimidine-2,4-diamine hydrochloride(1335247-35-2)

Safety Data

• Hazardous Substances Data: 1335247-35-2(Hazardous Substances Data)

Upstream product

• 21038-66-4 1H-Pyrido[2,3-d]pyrimidine-2,4-dione 
• 126728-20-9 2,4-dichloropyrido[2,3-d]pyrimidine 
• 73918-56-6 4-Bromophenethylamine 

Relevant articles and documents

New insights into the structural requirements for pro-apoptotic agents based on 2,4-diaminoquinazoline, 2,4-diaminopyrido[2,3-d]pyrimidine and 2,4-diaminopyrimidine derivatives

As a continuation of our work on new anti-tumoral derivatives with selective pro-apoptotic activity in cancer cells, we describe the synthesis and the preliminary evaluation of the cytotoxic and pro-apoptotic activities of a series of pyrimidin-2,4-diamine derivatives that are structurally related to quinazolin-2,4-diamine and pyrido[2,3-d]pyrimidin-2,4-diamine derivatives. We also describe the structure-activity relationship studies carried out on four series' of quinazolin-2,4-diamine, 2-(alkylsulfanyl)-N-alkyl- and 2-(alkylsulfanyl)-N-alkylarylpyrido[2,3-d]pyrimidine and pyrimidin-2,4-diamine derivatives. The proposed preliminary pharmacophore consists of a flat heterocyclic ring, preferably a pyrido[2,3-d]pyrimidine, with two equivalent alkylarylamine chains, preferably N-benzyl- or N-ethylphenylamine, located in positions 2 and 4 of the ring, and with a preferred ALogP in the range 4.5-5.5. The nitrogen present in the central ring can act as hydrogen bond acceptors (HBA) whereas the amino group in the 4-position can act as a donor (HBD) or an HBA and the amino group in the 2-position can act as an HBD. On the basis of the analyzed structural profiles, different mechanisms of action can be suggested for the quinazolin-2,4-diamine, the 2-(alkylsulfanyl)-N-alkylpyrido[2,3-d] pyrimidin-4-amine and the pyrido[2,3-d]pyrimidin-2,4-diamine derivatives.